Doctor profile · Federal record
Dr. STACEY EHLERS-MILLETT, R.N., C.N.P.
Nurse Practitioner · Gerontology Nurse Practitioner · SAINT PAUL, MN
- NPI 1689636615
- Accepts Medicare
- 24 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
435 PHALEN BLVD
SAINT PAUL, MN 551305302
(651) 254-8680
fax (651) 254-8656 - Mailing address
-
8170 33RD AVE S, MS 21110Q
MINNEAPOLIS, MN 554254516
Credentials & registration
- NPI registered
- April 2006 — 20 yrs on file
- Profile last updated
- December 8, 2021
- Year of graduation
- 2002 — 24 yrs since
- Specialty taxonomy
- 363L00000X — NUCC code
- State licenses (2)
- Minnesota #3329 · Minnesota #R123301-2
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1689636615. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
132
Distinct HCPCS
3
Medicare allowed
$4,904
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
36415 |
Insertion of needle into vein for collection of blood sample | 68 | 36 | $8 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 37 | 32 | $81 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 27 | 25 | $50 |
In context: peer comparison
Among 40 peers in this city , average services per provider: 61. This provider delivers 2.2× the peer median.Medicare Part D · 2023
Top prescriptions
Total claims
295
Patients
31
Total drug cost
$767,363
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Mesalamine | Generic | 56 | 17 | $45,625 |
| Omeprazole | Generic | 35 | 14 | $663 |
| Linzess (Linaclotide) | Brand | 25 | 0 | $20,126 |
| Azathioprine | Generic | 22 | 0 | $1,220 |
| Famotidine | Generic | 22 | 0 | $395 |
| Pentasa (Mesalamine) | Brand | 22 | 0 | $8,398 |
| Sodium Chloride (0.9 % Sodium Chloride) | Brand | 18 | 0 | $110 |
| Budesonide Dr (Budesonide) | Brand | 16 | 0 | $2,594 |
| Humira(Cf) Pen (Adalimumab) | Brand | 16 | 0 | $215,228 |
| Entyvio (Vedolizumab) | Brand | 13 | 0 | $111,982 |